
Daraxonrasib shows early signal against lung cancer in New England Journal of Medicine trial
An early clinical trial suggests the newly approved pancreatic cancer drug daraxonrasib may also shrink advanced lung tumors, with larger studies now underway.
Open signal ↗









































